Analog Devices sees growth accelerating

Analog Devices expects annual revenue growth to average 7% to 10% over the next five years, the chip maker told analysts at a meeting Tuesday morning at the company’s headquarters near Boston.

As the name implies, Analog Devices (ticker: ADI) is a leader in the market for chips that measure, sense, and interpret real-world information and convert that data into digital form. As CFO Prashanth Mahendra-Rajah said in an interview, the company has a broad portfolio of more than 75,000 individual parts, which it sells to more than 125,000 customers.

JPMorgan Multi-Asset Growth & Income plc (LON:MATE) combines sustainable income and capital growth from globally diversified investments. The Investment Trust’s multi-asset investing approach aims to achieve a long-term total return of 6% per annum and an initial annual dividend of 4% paid quarterly. This provides an attractive income investing and capital growth opportunity while seeking to maintain lower levels of portfolio volatility than a traditional equity portfolio.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn

More articles like this

US FDA approves new Bristol Myers cancer immunotherapy

Bristol Myers Squibb Co said on Friday that U.S. regulators approved the first drug in a new class of cancer immunotherapies as an initial treatment for advanced melanoma, the deadliest form of skin cancer. The company

Procter & Gamble-owned Pantene partners with impressive female collective

THE WHAT? Procter & Gamble-owned Pantene has teamed up with ‘impressive, strong, modern, multi-hyphenate women’ to form the new Pantene Conditioner Collective. THE DETAILS Partners of the collective include Chloe Fineman, who features on Saturday Night Live and Dickinson, comedian Meg

Procter & Gamble’s sales jump

Shoppers shrugged off rising prices last year on products like Pampers diapers and Charmin toilet paper, Procter & Gamble said on Wednesday in announcing a jump in its second-quarter earnings. The consumer goods giant reported that

Abbvie looks to crack the cystic fibrosis code

When it comes to cystic fibrosis Vertex is the undisputed heavyweight, but this has not stopped other groups from taking it on. Abbvie is the latest challenger, and data due this quarter could give clues about

Italy to receive 40,000 Merck antiviral drug doses next week

Italy will receive around 40,000 doses of Merck & Co’s (MRK.N) COVID-19 antiviral drug next week, which will add to nearly 12,000 already distributed to hospitals, the special COVID-19 commissioner said on Sunday. “They are intended